Citeline Podcasts

Pink Sheet reporters and editors in the US and Europe consider the growth and impact of Project Orbis after a year in which two major regulators joined the program, but several countries did not keep up with the US approval pace.

More On These Topics From The Pink Sheet

Project Orbis 2023: FDA Approves Six New Cancer Drugs, But Partner Nations Lag Behind: https://pink.citeline.com/PS149452/Project-Orbis-2023-FDA-Approves-Six-New-Cancer-Drugs-But-Partner-Nations-Lag-Behind

Project Orbis: More Cancer Drugs Available In Scotland Than England: https://pink.citeline.com/PS149063/Project-Orbis-More-Cancer-Drugs-Available-In-Scotland-Than-England

EMA Will Observe Project Orbis In Effort To Increase Collaboration: https://pink.citeline.com/PS148458/EMA-Will-Observe-Project-Orbis-In-Effort-To-Increase-Collaboration

US FDA Eyes Project Orbis-Type Approach For Cell And Gene Therapies: https://pink.citeline.com/PS147730/US-FDA-Eyes-Project-Orbis-Type-Approach-For-Cell-And-Gene-Therapies

Brian Yang and Dexter Yan discuss Biokin/BMS's ADC deal, WuXi Biologics' share price drop, BlissBio's recent developments and Pfizer's divestment of Prevenar 13 commercial rights in China to a Chinese local partner.

https://scrip.citeline.com/SC149497/Chinese-Language-Podcast-BiokinBMS-Deal-Developments-At-Pfizer-BlissBio-WuXi-Biologics

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: another acquisition for AbbVie; Roche buys into the obesity market; J&J’s oral immunology push; oral incretins advance; and AstraZeneca on Chinese innovation.

https://scrip.citeline.com/SC149480/Quick-Listen-Scrips-Five-MustKnow-Things

In this episode, HBW Insight speaks to Aurélie Perrichet, regional director, Europe at the International Fragrance Association. We discussed the implications of planned revisions to the European Commission’s Classification, Labeling and Packaging (CLP) regulation, which may re-categorize biological materials as mixtures, from their current status as substances. Perrichet also speculated how the proposed change could reduce the number of available essential oils and other types of fragrance and flavor materials available.

최근 제프리스 헬스케어 컨퍼런스에서 발표된 제약바이오산업의 생성형인공지능 적용사례에 대한 Scrip 기사를 요약한 내용입니다.

https://scrip.citeline.com/SC149412/As-Biopharma-Adopts-Generative-AI-The-People-Element-Is-Crucial-To-Success

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.

https://scrip.citeline.com/SC149443/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies (:35), the agency’s policy for using background music in direct-to-consumer advertising (7:27), and the FDA’s new incoming principal deputy commissioner (13:44).

More On These Topics From The Pink Sheet

CAR-T Malignancy Reports Could Temper Excitement For Use Beyond Oncology: https://pink.citeline.com/PS149420/CAR-T-Malignancy-Reports-Could-Temper-Excitement-For-Use-Beyond-Oncology

Background Music During Risk Segment Of Rx Drug Ads: FDA Explains Its Policy: https://pink.citeline.com/PS149411/Background-Music-During-Risk-Segment-Of-Rx-Drug-Ads-FDA-Explains-Its-Policy

US FDA Chief Scientist Bumpus Will Become Principal Deputy Commissioner: https://pink.citeline.com/PS149428/US-FDA-Chief-Scientist-Bumpus-Will-Become-Principal-Deputy-Commissioner

In this podcast, In Vivo speaks to Sara Barrington, CEO of Verici DX. During the discussion, Barrington outlines the current challenges facing patients post-transplant, why current diagnostics are inadequate, and where the overall transplant market is headed, considering the rise of home dialysis and the potential future for xenotransplants.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.

https://scrip.citeline.com/SC149413/Quick-Listen-Scrips-Five-MustKnow-Things

Datamonitor Healthcare’s Epidemiology team (Ridwaan Ibrahim, Lucia Rodriguez-Garcia, Maya Trivedy, and Asma Ali) discuss the current trends in epidemiology throughout the world, and how epidemiology data is being used to support drug discovery and improve health outcomes.

Topics discussed include epidemiology methodologies, Alzheimer’s Disease, non-communicable diseases in Africa, genetic epidemiology, pollution, and increasing cancer rates.

Other platforms

Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​​

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/​

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67